Published Online: April 17, 2020. doi:10.1001/jama.2020.6437
Conflict of Interest Disclosures: Dr Aronoff reported receiving funding from the National Center for Advancing Translational Sciences, Pfizer, Cayman Chemical Co, March of Dimes, National Institute of Allergy and Infectious Diseases, and Eunice Kennedy Shriver National Institute of Child Health and Human Development and serving as an advisory board consultant for Summit Therapeutics, NAEJA-RGM Pharmaceuticals, BLC, and Sanofi Pasteur. Dr Desai reported no disclosures.
Sources: Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US: a clinical update. JAMA. Published online April 6, 2020. doi:10.1001/jama.2020.5788
Bourouiba L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19. JAMA. Published online March 26, 2020. doi:10.1001/jama.2020.4756
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565